Form 4: Maravai LifeSciences Director Gregory Lucier Awarded Significant Restricted Stock Units

Maravai LifeSciences Holdings, Inc. Director Gregory T. Lucier was awarded 89,139 restricted stock units, valued at $2.16 per unit, under the company's 2020 Omnibus Incentive Plan.

Summary

• Gregory T. Lucier, a Director of Maravai LifeSciences Holdings, Inc. (MRVI), acquired 89,139 shares of Class A Common Stock.
• The transaction occurred on June 16, 2025.
• These shares were awarded as restricted stock units (RSUs) under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan.
• The RSUs have a per-unit value of $2.16.
• The RSUs will vest in full upon the earlier of one year from the grant date (June 16, 2026) or the date of the 2026 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders.
• Following this transaction, Mr. Lucier directly beneficially owns 144,262 shares of Class A Common Stock and indirectly owns 20,645 shares through a Family Partnership.

Sentiment

Score: 7

Explanation: The acquisition of restricted stock units by a director is generally viewed positively as it aligns the director's interests with those of shareholders and is a standard component of executive compensation, indicating stability and commitment.

Positives

• Director Gregory T. Lucier acquired 89,139 shares of Class A Common Stock, aligning his interests with shareholders.
• The award is part of an established incentive plan, suggesting management retention and performance incentives.

Future Outlook

The restricted stock units are set to vest in full upon the earlier of one year from the grant date (June 16, 2026) or the date of the 2026 annual meeting of stockholders, indicating a future commitment and alignment of the director's interests with long-term company performance.

Industry Context

The award of restricted stock units to a director is a common practice in the life sciences industry, as well as across other sectors, to incentivize long-term commitment and align executive interests with shareholder value creation. Such equity-based compensation is a standard component of corporate governance and talent retention strategies.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) as a form of equity compensation for directors is a widely adopted practice across publicly traded companies, including those in the life sciences sector.
• This method is consistent with industry standards for executive and director compensation, aiming to foster long-term alignment between leadership and shareholder interests.
• While specific RSU grant sizes and vesting schedules vary by company (e.g., compared to grants at biotech firms like Amgen or Gilead Sciences, or diagnostic companies like Quest Diagnostics), the underlying principle of performance-based equity awards remains a benchmark for corporate governance.

Corporate Governance

Related Party Transactions

• Gregory T. Lucier indirectly owns 20,645 shares of Class A Common Stock through a Family Partnership, which is disclosed as part of his beneficial ownership.

Stakeholder Impact

• Shareholders: The award of restricted stock units to a director aligns management's long-term interests with shareholder value creation, potentially fostering confidence.
• Employees: While not directly impacting all employees, such incentive plans can signal a commitment to performance-based compensation at leadership levels.

Next Steps

• Vesting of the 89,139 restricted stock units upon the earlier of June 16, 2026, or the date of the 2026 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders.

Key Dates

Keywords

Maravai LifeSciences, MRVI, Form 4, insider transaction, stock award, restricted stock units, RSU, director compensation, equity incentive plan